The Supera™ Peripheral Stent is indicated for the superficial femoral artery (SFA) and the proximal popliteal artery. Engineered by a unique interwoven wire technology, this nitinol stent offers physicians unmatched clinical outcomes5-16 across varied lesion complexities and lengths.1-4
To learn more about Supera™ Stent, simply request a free demonstration and your local Abbott representative will be in touch shortly.
The Supera™ Stent is known for the excellence of its clinical outcomes during percutaneous transluminal angioplasty (PTA) procedures, since this peripheral stent has been studied in more than 2,000 patients and 17 studies worldwide.3,5-16
PATENCY (K-M) AT 1 YEAR
When nominally deployed*
FREEDOM FROM TLR AT 3 YEARS
When nominally deployed*
*Nominal deployment is defined as the stent length upon deployment being within +/- 10% of the labeled stent length. This data is from a non-powered post-hoc analysis.
Demonstrates excellent clinical outcomes
Supera™ Stent demonstrated excellent 1 yr patency and 3 yr freedom from TLR in the SUPERB trial.5
1
Unmatched clinical outcomes
Demonstrated unmatched clinical outcomes in simple lesions across US pivotal stent trials5-20
2
Consistent across lesion length
Exhibits consistent 1-year primary patency results regardless of lesion length17-25
3
Strong outcomes in calcification
Reveals strong clinical outcomes in severely calcified lesions at year 3 years5
* Study reported a majority with Trans-Atlantic Inter-Society Consensus Document (TASC) A & B lesions and/or Rutherford class 2 or 3 lesions
Design Matters
Unlike any other stent design platform, the Supera™ Stent is uniquely designed to keep vessels open with its distinct platform, created by interwoven individual, flexible nitinol wires
High Compression Resistance26
4x greater strength for compression resistance—so it can maintain a round, open lumen, which can be especially beneficial in calcified lesions
Low Chronic Outward Force26
With 1:1 stent to vessel sizing, low chronic outward force results in minimal vessel injury28
High Flexibility27 and Fracture Resistance5
Unparalleled flexibility,27 which mimics the natural structure and movement of the anatomy29-31
Zero stent fractures reported at 1 year in over 2,000 patients across 17 studies3,5-20
REFERENCES
Treitl, K.M., et al. European Radiology.2017; 10.1007.
Garcia L. et al., Catheterization and Cardiovascular Interventions 2017 Jun 1;89(7):1259-1267
Brescia AA. et al., J Vasc Surg. 2015 Jun;61(6):1472-8
Palena L.M. et al. Catheterization and Cardiovascular Intervention.2016.
Garcia L. et al., Catheterization and Cardiovascular Interventions 2017 Jun 1;89(7):1259-1267.
Gray W. et al., Lancet 2018;392:1541-51.
Dake M. et al., Circulation. 2016;133:1472-1483.
Laird J. et al., Circ Cardiovasc Interv. 2010;3:267-276.
Laird J et al., J Endovasc Ther. 2012;19:1–9.
S.M.A.R.T. Control IFU.
Jaff, M., SMART Nitinol Self-Expanding Stent in the Treatment of Obstructive Superficial Femoral Artery Disease: Three-year Clinical Outcomes from the STROLL Trial. ISET 2014.
Matsumura J et al., J Vasc Surg 2013;58:73-83.
Rocha-Singh, K., 3-Year Results of the DURABILITY II Study. VIVA 2013.
US Innova IFU.
US Pulsar IFU.
Ohki T. et al. J Vasc Surg. 2016 Feb;63(2):370-6.
Treitl, K.M., et al. European Radiology. 2017; 10.1007
Garcia L. et al. Circ Cardiovasc Interv. 2015;8:e000937
Scheinert D. et al., J Endovasc Ther. 2011 Dec;18(6):745-52.
San Norberto EM. et al., Ann Vasc Surg. 2017 May;41:186-195.
Werner M. et al., EuroIntervention. 2014 Nov;10(7):861-8.
George JC. et al., J Vasc Interv Radiol. 2014 Jun;25(6):954-61.
Montero-Baker M. et al., J Vasc Surg. 2016 Oct;64(4):1002-8.
Brescia A. et al. J Vasc Surg. 2015 Mar 6. pii: S0741-5214(15)00132-9
Palena L.M. et al. Catheterization and Cardiovascular Interventions 2016
Competitors tested include Astron Pulsar-18, Complete SE, EverFlex, Innova, LifeStent, Misago, S.M.A.R.T., and Zilver PTX. Test(s) performed by and data on file at Abbott.
Flexibility is defined as kink resistance. Competitors tested include Astron Pulsar-18, Complete SE, EverFlex, Innova, LifeStent, Misago, S.M.A.R.T., and Zilver PTX. Test(s) performed by and data on file at Abbott
Zhao HQ et al. Cardiovasc Intervent Radiol. 2009;32(4):720-6
DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?
CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.
Precautions
Please be sure to read it.
The following pages are intended for medical professionals and provide information on the proper use of products (medical devices, etc.) of Abbott Medical Japan GK.
The information provided here is not intended to provide information to patients and the general public.
Are you a healthcare professional?
Test
yes
Precautions
Please be sure to read it.
The following pages are intended for medical professionals and provide information on the proper use of products (medical devices, etc.) of Abbott Medical Japan GK.
The information provided here is not intended to provide information to patients and the general public.
Are you a healthcare professional?
Test
[prod, crx3, samplecontent, publish, crx3tar]
test
DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?
CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.
Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.
Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.
The following pages are intended for medical professionals and provide information on the proper use of products (medical devices, etc.) of Abbott Medical Japan GK.
The information provided here is not intended to provide information to patients and the general public.